John Rim of Samsung Biologics: "Reviewing New Modalities"
Obesity Drugs

At BIO USA,
Competitors Also Vow to "Establish New Modalities"

Global Contract Development and Manufacturing Organizations (CDMOs) are employing divergent investment strategies to seize leadership in next-generation modalities (therapeutic approaches). The competition among the top three players is intensifying as they vie to secure new revenue streams beyond their traditional stronghold of antibody drug production, including increasingly prominent areas such as peptides, cell therapies, and gene therapies (CGT).

[BIO USA] Samsung Biologics Eyes CGT and Peptides... CDMO Big 3 Compete to Lead Next-Generation Modality Market View original image

According to the industry on June 26, Samsung Biologics is considering establishing next-generation modality manufacturing facilities—such as peptides, adeno-associated viruses (AAV), and cell and gene therapies (CGT)—at its third bio campus in Songdo, Incheon, where partial construction began last month. Samsung Biologics plans to invest 7 trillion won to build the pharmaceutical manufacturing complex in two phases by 2034. During a press conference at the "BIO International Convention 2026 (BIO USA)" held in San Diego, USA, from June 22 to 25 (local time), John Rim, CEO of Samsung Biologics, stated, "Since antibodies are already being produced at Campuses 1 and 2, we are considering the possibility of peptide production, such as glucagon-like peptide-1 (GLP-1), at Campus 3. AAV and CGT are also under review," he said. With its existing antibody production capabilities far outpacing global competitors, the company is now concretely expanding its strategy into new modalities.


With technological advances such as in vivo gene editing, the market for new modalities like next-generation CGT and AAV is gradually expanding. CGT refers to biopharmaceuticals that fundamentally treat cancer and rare genetic diseases by manipulating a patient's cells or correcting defective genes to normal ones. A representative product is CAR-T (chimeric antigen receptor T-cell) therapy, which engineers immune cells to attack cancer cells. Examples include Novartis’ "Kymriah," a treatment for refractory blood cancer, and the indications are now expanding to include solid tumors and autoimmune diseases. AAV (adeno-associated virus) is a core "carrier (viral vector)" used to deliver gene therapies directly to target cells within a patient's body. As it is non-pathogenic and can deliver genes effectively, it forms the backbone of so-called "one-shot" therapies that aim to cure diseases with a single dose. Samsung Biologics plans to proactively establish manufacturing infrastructure for next-generation modalities to secure future growth engines and maintain its leadership as the world’s top CDMO.

Samsung BioLogics booth at the world's largest bio-pharmaceutical expo, the 2026 BIO International Convention (BIO USA), which opened on the 22nd of this month (local time) in San Diego, USA. Photo by Minjae Kwak

Samsung BioLogics booth at the world's largest bio-pharmaceutical expo, the 2026 BIO International Convention (BIO USA), which opened on the 22nd of this month (local time) in San Diego, USA. Photo by Minjae Kwak

View original image

At the BIO USA venue, it was evident that global CDMO companies are also focusing on expanding their facilities to capture the new modality market. Fujifilm has established large-scale production capabilities for CGT and mRNA (messenger RNA) in the United States. The company operates viral vector and cell manufacturing facilities in College Station, Texas, and has acquired a self-cell therapy manufacturing site of approximately 8,260 square meters in Thousand Oaks, California, where it is expanding cleanroom suites to support commercial-scale production. In Madison, Wisconsin, the company is investing about 200 million dollars (approximately 309 billion won) to build a new site specializing in induced pluripotent stem cells (iPSC), aiming to begin operations within the year. In Toyama, Japan, the company operates a one-stop facility that covers everything from mRNA synthesis to LNP (lipid nanoparticle) encapsulation and final product filling.


A representative from Fujifilm's process development division, whom we met at the BIO USA exhibition booth, commented, "With the emergence of new, complex modalities such as bispecific antibodies and rare drugs, actual demand for small-to-medium scale production (2,000–5,000 liters) is increasing." He added, "In response to this market shift, we are expanding mid-scale production lines, not only through large facilities but also at sites in the UK and Japan. The company’s ultimate goal is to become an ‘end-to-end’ supplier, covering the entire cycle from the initial discovery and screening stage to large-scale commercial production."



Lonza is designating its Visp, Switzerland site as a key manufacturing base for CGT and bioconjugates, and is ramping up investments there. Following the large-scale expansion of commercial mRNA and LNP (lipid nanoparticle) production lines at the Visp plant, the company has recently decided to add two multi-purpose bioconjugate manufacturing facilities with a combined capacity of about 1,200 liters, targeting operational launch by 2028. Lonza offers a portfolio that spans autologous and allogeneic T-cell therapies and viral vectors, and is pursuing a strategy to lower commercialization risk by integrating production capabilities from early clinical development through to large-scale commercial supply.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing